The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picks3i Group Regulatory News (III)

Share Price Information for 3i Group (III)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,919.00
Bid: 2,760.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 161.00 (5.833%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 2,919.00
III Live PriceLast checked at -
3i Group is an Investment Trust

To provide its shareholders with quoted access to private equity and infrastructure returns, its main focus is on making quoted and unquoted equity and/ or debt investments in businesses and funds in Europe, Asia and the Americas.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FY2022 Q1 performance update

22 Jul 2021 07:00

RNS Number : 0517G
3i Group PLC
22 July 2021
 

22 July 2021

3i Group plc

FY2022 Q1 performance update

 

A strong start to FY2022 

· Increase in NAV per share to 1,063 pence (31 March 2021: 947 pence) and total return of 12.2% for the three months to 30 June 2021

· Another strong quarter from the Private Equity portfolio with notable contributions from Action, AES, Basic-Fit, BoConcept, GartenHaus, Luqom, Q Holding, Royal Sanders, SaniSure and Tato

· A powerful performance from Action in the quarter with very good sales and EBITDA growth. EBITDA for the quarter was €205 million, 107% above 2020 and 67% above 2019. Sales for the quarter were €1,688 million, 52% above 2020 and 39% above 2019

· Received £84 million of refinancing proceeds from Royal Sanders and completed one bolt-on acquisition for Luqom with no further investment from 3i

· 3i Infrastructure plc ("3iN") completed its investment in DNS:NET and a bolt-on acquisition for Joulz, an existing portfolio company

· Both investment divisions remain active with a healthy pipeline of new investment opportunities, bolt-ons and refinancing and realisation transactions

 

Simon Borrows, Chief Executive, commented:

 

"3i has made a strong start to its new financial year. Our investment portfolios in Private Equity and Infrastructure are well positioned for another year of good progress. Action's impressive performance continues, and the group is trading very well now that all stores have fully reopened. We are working on a number of investment and realisation opportunities across the investment teams, but we remain highly selective when deploying new capital in the current environment."

 

 

Private Equity

 

Portfolio performance and valuation at 30 June 2021

 

The Private Equity portfolio generated a strong return for the quarter, including a marked step-up in Action's performance. Sales of €1,688 million in the quarter were up 31% from Q1 2021, while EBITDA increased by 151% over the same period. At the start of 2021, Action was impacted by widespread store closures and restrictions. However, the business executed an impressive trading recovery through the end of its Q1 2021 and in Q2 2021. Like-for-like ("LFL") sales comparisons between 2020 and 2021 are difficult due to differing store closures and restrictions over the two periods. However, June (P6) is the one period with all stores substantially open in both years: P6, 2020 delivered 11% LFL growth; P6, 2021 delivered 14.7% LFL growth. Action opened 63 new stores in the quarter and continues to target c.300 new stores in 2021. Cash flow has been strong with the group's cash balance now over €700 million.

 

At 30 June 2021, Action was valued using the last twelve months' ("LTM") run-rate earnings to 30 June 2021 (€783 million) and an unchanged multiple of 18.5x net of the liquidity discount, resulting in a valuation of £5,512 million (31 March 2021: £4,566 million) for 3i's 52.7% equity stake.

The remainder of the Private Equity portfolio generated good returns in the quarter, with good momentum across most of our top 20 assets. Our portfolio is well positioned to benefit from a number of structural growth trends which have continued to support strong performance in a number of our investments, and particularly in assets operating in markets such as biologics (SaniSure), e-commerce (Luqom and GartenHaus), or with exposure to the value-for-money theme (Royal Sanders, Hans Anders). BoConcept and Q Holding are also trading significantly ahead of last year. Of our top 20 portfolio companies, 94% by value grew their LTM adjusted earnings to March 2021.

 

Private Equity investments and realisations

 

In April 2021, Luqom funded and completed the bolt-on acquisition of Lampemesteren, an online retailer of premium lighting products in the Nordic region.

 

In June 2021, we received proceeds of £84 million, of which £4 million was recognised as income, from the refinancing of Royal Sanders.

 

 

Infrastructure

 

3iN's share price was stable in the three months to 30 June 2021 closing at 298 pence (31 March 2021: 296 pence), valuing 3i's 30% stake at £801 million (31 March 2021: £797 million). We also recognised dividend income of £13 million from 3iN in the quarter. In the period, 3iN completed the acquisition of a 60% stake in DNS:NET, an independent telecommunications provider in Germany for €182 million, and Joulz, one of 3iN's existing portfolio companies, completed the acquisition of Zonel Energy, a provider of solar rooftop solutions to businesses across the Netherlands.

 

 

Scandlines

 

Scandlines continued to be impacted by travel restrictions in the three months to 30 June 2021. However, freight continued to perform strongly with volumes ahead of the prior year YTD. Leisure volumes started to pick up towards the end of the period. Our core DCF valuation assumptions remain consistent with the March 2021 valuation.

 

 

Top 10 investments by value at 30 June 2021

 

 

 

 

Valuation

Valuation

 

 

Valuation

Valuation

Mar-21

Jun-21

 

 

basis

currency

£m

£m

Activity in the quarter

Action

Earnings

EUR

4,566

5,512

 

3iN

Quoted

GBP

797

801

 

Cirtec Medical

Earnings

USD

444

450

 

Scandlines

DCF

EUR

435

449

 

Tato

Earnings

GBP

368

386

 

Luqom

Earnings

EUR

307

359

Completed the bolt-on acquisition of Lampemesteren in April 2021.

Royal Sanders

Earnings

EUR

364

291

Returned £84 million of proceeds to 3i.

Evernex

Earnings

EUR

281

278

 

Hans Anders

Earnings

EUR

262

270

 

WP

Earnings

EUR

259

263

 

 

The 10 investments in this table comprise 78% (31 March 2021: 78%) of the total Proprietary Capital portfolio value of £11,558 million (31 March 2021: £10,408 million).

 

 

Total return and NAV position

 

We recognised a net gain on foreign exchange of £47 million in the quarter, as sterling weakened against the euro. Based on the balance sheet at 30 June 2021, 69% of the Group's net assets were denominated in euro and 15% in US dollar. A 1% movement in the euro and US dollar would result in a total return movement of £70 million and £15 million respectively, net of any hedging. The diluted NAV per share increased to 1,063 pence (31 March 2021: 947 pence) or 1,042 pence after deducting the 21 pence per share second FY2021 dividend, which will be paid on 23 July 2021.

 

 

Balance sheet

 

At 30 June 2021, cash was £286 million (31 March 2021: £225 million), and including our undrawn £500 million revolving credit facility liquidity was £786 million (31 March 2021: £725 million). Net debt was £689 million and gearing 6.7% (31 March 2021: £750 million and 8.2%). The 21 pence per share second FY2021 dividend, totaling £203 million, will be paid on 23 July 2021.

 

 

- ENDS -

 

 

 

Notes

 

1.

Balance sheet values are stated net of foreign exchange translation. Where applicable, the GBP equivalents at 30 June 2021 in this update have been calculated at a currency exchange rate of 1.1652: £1 and $1.3812: £1 respectively.

2.

At 30 June 2021 3i had 969 million diluted shares.

3.

Action was valued using a post discount run-rate EBITDA multiple of 18.5x based on its run-rate earnings to 30 June 2021.

 

 

For further information, please contact:

Silvia SantoroInvestor Relations DirectorTel: 020 7975 3258

 

Kathryn van der KroftCommunications DirectorTel: 020 7975 3021

 

 

About 3i Group

3i is a leading international investment manager focused on mid-market Private Equity and Infrastructure. Our core investment markets are northern Europe and North America. For further information, please visit: www.3i.com.

 

All statements in this performance update relate to the three-month period ended 30 June 2021 unless otherwise stated. The financial information is unaudited and is presented on 3i's non-GAAP Investment basis in order to provide users with the most appropriate description of the drivers of 3i's performance. Net asset value ("NAV") and total return are the same on the Investment basis and on an IFRS basis. Details of the differences between 3i's consolidated financial statements prepared on an IFRS basis and under the Investment basis are provided in the 2021 Annual report and accounts. There have been no material changes to the financial position of 3i from the end of this quarter to the date of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUASBRAVUBUAR
Date   Source Headline
10th May 202411:47 amRNSDirector/PDMR Shareholding
9th May 20247:00 amRNSResults for the year to 31 March 2024
1st May 20248:58 amRNSDirector/PDMR Shareholding
30th Apr 20244:34 pmRNSTotal Voting Rights
2nd Apr 20248:01 amRNSPortfolio Update
28th Mar 20241:02 pmRNSTotal Voting Rights
28th Mar 20241:00 pmRNSDirector/PDMR Shareholding
21st Mar 20241:53 pmRNSDirector/PDMR Shareholding
21st Mar 20247:00 amRNSAction Capital Markets Seminar & portfolio update
1st Mar 202410:11 amRNSDirector/PDMR Shareholding
29th Feb 20244:21 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNS3i Group plc - Q3 performance update
31st Jan 20244:17 pmRNSTotal Voting Rights
31st Jan 20244:14 pmRNSDirector/PDMR Shareholding
4th Jan 20243:36 pmRNSTotal Voting Rights
4th Jan 20243:35 pmRNSDirector/PDMR Shareholding
3rd Jan 202412:00 pmRNSPortfolio Update
8th Dec 20231:11 pmRNSBlock listing Interim Review
30th Nov 20234:55 pmRNSTotal Voting Rights
30th Nov 20234:51 pmRNSDirector/PDMR Shareholding
23rd Nov 202311:11 amRNSDirector Declaration
20th Nov 20239:13 amRNSDirector Declaration
9th Nov 20232:29 pmRNSDirector/PDMR Shareholding
9th Nov 202311:49 amRNSDoc re. Half Yearly Report 2023
9th Nov 20237:00 amRNSHalf-year Report
31st Oct 20233:29 pmRNSTotal Voting Rights
31st Oct 20233:27 pmRNSDirector/PDMR Shareholding
2nd Oct 202312:58 pmRNSDirector/PDMR Shareholding
2nd Oct 202310:36 amRNSPortfolio Update
28th Sep 20231:35 pmRNSDirector/PDMR Shareholding
20th Sep 20237:00 amRNSUpdate on portfolio and Capital Markets Seminar
12th Sep 202310:43 amRNSDirector/PDMR Shareholding
4th Sep 202310:41 amRNSDirector/PDMR Shareholding
31st Aug 20233:56 pmRNSTotal Voting Rights
31st Aug 20233:52 pmRNSDirector/PDMR Shareholding
1st Aug 202311:40 amRNSDirector/PDMR Shareholding
31st Jul 20234:31 pmRNSTotal Voting Rights
31st Jul 20234:27 pmRNSDirector/PDMR Shareholding
20th Jul 20237:00 amRNSFY2024 Q1 performance update
3rd Jul 202310:25 amRNSPortfolio Update
30th Jun 20233:43 pmRNSTotal Voting Rights
30th Jun 20233:37 pmRNSDirector/PDMR Shareholding
30th Jun 202311:01 amRNSDirector/PDMR Shareholding
29th Jun 20235:00 pmRNSDirectorate Change
29th Jun 20233:46 pmRNSDirector/PDMR Shareholding
29th Jun 20233:31 pmRNSDoc re. AGM Resolutions
29th Jun 20233:30 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM and portfolio update
28th Jun 20232:34 pmRNSDirector/PDMR Shareholding
12th Jun 20232:33 pmRNSPublication of a Prospectus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.